Correction to: Selenium enhances TRPA1 channel-mediated activity of temozolomide in SH-SY5Y neuroblastoma cells
Related Experiment Video
Updated: Dec 25, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Birol Özkal1, İshak Suat Övey2
1Department of Neurosurgery, School of Medicine, Alanya Alaaddin Keykubat University, Alanya, 07400, Antalya, Turkey. birolozkal@gmail.com.
Abstract:
The original version of this article unfortunately contained few errors. The dose of sodium selenite was incorrectly indicated as 100 μM in the published version of "Selenium enhances TRPA1 channel-mediated activity of temozolomide in SH-SY5Y neuroblastoma cells". The correct indication of sodium selenite is 5 µM. Additionally the authors accidenttally referred to reference 11 instead of reference 10 in Group 6.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

